Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H46O |
| Molecular Weight | 326.6 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCCCCCCCCO
InChI
InChIKey=NOPFSRXAKWQILS-UHFFFAOYSA-N
InChI=1S/C22H46O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h23H,2-22H2,1H3
DescriptionSources: http://www.drugbank.ca/drugs/DB00632Curator's Comment: Description was created based on several sources, including
Sources: http://www.drugbank.ca/drugs/DB00632
Curator's Comment: Description was created based on several sources, including
Docosanol is a saturated 22-carbon aliphatic alcohol which exhibits antiviral activity against many lipid enveloped viruses including herpes simplex virus (HSV). Docosanol speeds the healing of cold sores and fever blisters on the face or lips. It also relieves the accompanying symptoms, including tingling, pain, burning, and itching. Docosanol works by inhibiting fusion between the human cell plasma membrane and the herpes simplex virus (HSV) envelope, thereby preventing viral entry into cells and subsequent viral replication. Unlike other cold-sore antivirals, docosanol does not act directly on the virus, and as such it is unlikely it will produce drug resistant mutants of HSV. Used for the topical treatment of recurrent oral-facial herpes simplex episodes (cold sores or fever blisters).
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: HIV-1 replication Sources: https://www.ncbi.nlm.nih.gov/pubmed/8825621 |
10.0 mM [EC50] | ||
Target ID: P03200 Gene ID: 3783713.0 Gene Symbol: NA Target Organism: Epstein-Barr virus (strain B95-8) (HHV-4) (Human herpesvirus 4) Sources: http://www.drugbank.ca/drugs/DB00632 |
|||
Target ID: CHEMBL2364696 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9864049 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Abreva Approved UseHerpes Labialis
Topical treatment of recurrent herpes labialis (perioral herpes, cold sores, fever blisters) Launch Date2000 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Nongenital herpes simplex virus. | 2010-11-01 |
|
| Soybean metabolites regulated in root hairs in response to the symbiotic bacterium Bradyrhizobium japonicum. | 2010-08 |
|
| LAP5 and LAP6 encode anther-specific proteins with similarity to chalcone synthase essential for pollen exine development in Arabidopsis. | 2010-07 |
|
| Rapid sampling of molecules via skin for diagnostic and forensic applications. | 2010-07 |
|
| A Potent, Broad-Spectrum Antiviral Agent that Targets Viral Membranes. | 2010-05 |
|
| Topical n-docosanol for management of recurrent herpes labialis. | 2010-04 |
|
| An ethnobotanical survey of medicinal plants in Babungo, Northwest Region, Cameroon. | 2010-02-15 |
|
| Nutritional bioactive components of wheat straw as affected by genotype and environment. | 2010-01 |
|
| Effect of combinations of antiviral drugs on herpes simplex encephalitis. | 2009-12-29 |
|
| Drugs associated with more suicidal ideations are also associated with more suicide attempts. | 2009-10-02 |
|
| [Study on the chemical constituents from Clematis brevicaudata]. | 2009-10 |
|
| Comments on study of paw pad lesions in dogs. | 2009-09-15 |
|
| [Tadenan treatment of prostatic adenoma]. | 2009-06-17 |
|
| Docosanol: new drug. Herpes labialis: barely more effective than an excipient. | 2009-06 |
|
| Policosanol, alpha-tocopherol, and moisture content as a function of timing of harvest of Switchgrass (Panicum virgatum L.). | 2009-05-13 |
|
| [Efficacy of tadenan in chronic prostatitis complicated by sterility]. | 2008-12-06 |
|
| Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. | 2008-06 |
|
| Single-day treatment for orolabial and genital herpes: a brief review of pathogenesis and pharmacology. | 2008-04 |
|
| Expression of transforming growth factor beta1 gene, basic fibroblast growth factor gene and hydroxyproline in diabetes-induced bladder dysfunction in a rat model. | 2008 |
|
| Management and prevention of recurrent herpes labialis in immunocompetent patients. | 2007-12 |
|
| Alpha-glucosidase inhibitors from Millettia conraui. | 2007-09 |
|
| Management of recurrent oral herpes simplex infections. | 2007-03 |
|
| [Studies on the chemical constituents of the aerial parts of Seseli mairei]. | 2007-01 |
|
| Structure and performance of cationic assembly dispersed in amphoteric surfactants solution as a shampoo for hair damaged by coloring. | 2007 |
|
| The lipid polyester composition of Arabidopsis thaliana and Brassica napus seeds. | 2006-12 |
|
| Weak first-order tilting transition in monolayers of mono- and bipolar docosanol derivatives. | 2006-11-09 |
|
| Self-assembled two-dimensional ordered arrays of tripod-type molecules on graphite. | 2006-07-04 |
|
| New antiviral agents. | 2006-04 |
|
| Two-dimensional miscibility studies--the analysis of interaction between long-chain alcohols and semifluorinated alkanes. | 2006-02-23 |
|
| [Modern pharmacotherapy of benign prostatic hyperplasia]. | 2005-11 |
|
| Low-dose tadenan protects the rabbit bladder from bilateral ischemia/ reperfusion-induced contractile dysfunction. | 2005-01 |
|
| Docosanol: a topical antiviral for herpes labialis. | 2004-12 |
|
| [Tadenan (Pygeum africanum extract) in the treatment of patients with benign prostatic hyperplasia]. | 2004-11-25 |
|
| Therapeutic options for herpes labialis, II: Topical agents. | 2004-07 |
|
| Two-dimensional packing patterns of amino acid surfactant and higher alcohols in an aqueous phase and their associated packing parameters. | 2004-05-15 |
|
| Molecular transfer and transport in noncovalent microcontact printing. | 2004-02-03 |
|
| Effect of topically applied resveratrol on cutaneous herpes simplex virus infections in hairless mice. | 2004-01 |
|
| Constituents of Hypericum laricifolium and their cyclooxygenase (COX) enzyme activities. | 2003-12 |
|
| Efficacy of docosanol. | 2003-09 |
|
| Cytotoxic activity of the root extract from Myoschilos oblongum. | 2003-07 |
|
| Effect of Pygeum africanum tadenan on micturition and prostate growth of the rat secondary to coadministered treatment and post-treatment with dihydrotestosterone. | 2003-02 |
|
| Study of detrusor dysfunction due to outlet obstruction: link between analysis of uroflows of men with benign prostatic hyperplasia and animal studies. | 2003 |
|
| Synergistic inhibition of herpesvirus replication by docosanol and antiviral nucleoside analogs. | 2002-11 |
|
| Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon. | 2002-10 |
|
| N-docosanol (Abreva) for herpes labialis: problems and questions. | 2002-09 |
|
| The toxicity of behenyl alcohol. II. Reproduction studies in rats and rabbits. | 2002-08 |
|
| The toxicity of behenyl alcohol. I. Genotoxicity and subchronic toxicity in rats and dogs. | 2002-08 |
|
| New drug approvals in 2000. | 2002-05-23 |
|
| n-Docosanol inhibits in vitro replication of HIV and other retroviruses. | 1996-01-01 |
|
| Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex. | 1991-12-01 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/docosanol-topical.html
Apply docosanol topical in a quantity sufficient to cover the affected lesions and immediately surrounding skin five times a day until the lesions are healed.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8825621
31 mM docosanol inhibited HIV-1 replication up to 82%
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
D06BB11
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
||
|
WHO-VATC |
QD06BB11
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
||
|
NCI_THESAURUS |
C281
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
661-19-8
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
PRIMARY | |||
|
DTXSID4027286
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
PRIMARY | |||
|
9G1OE216XY
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
PRIMARY | |||
|
100000088244
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
PRIMARY | |||
|
m4714
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
PRIMARY | Merck Index | ||
|
DB00632
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
PRIMARY | |||
|
CHEMBL1200453
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
PRIMARY | |||
|
940
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
PRIMARY | |||
|
C47498
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
PRIMARY | |||
|
31000
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
PRIMARY | |||
|
9G1OE216XY
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
PRIMARY | |||
|
8407
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
PRIMARY | |||
|
30303-65-2
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
NON-SPECIFIC SUBSTITUTION | |||
|
594680
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
PRIMARY | RxNorm | ||
|
12620
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
PRIMARY | |||
|
5739
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
PRIMARY | |||
|
LL-43
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
PRIMARY | |||
|
SUB21986
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
PRIMARY | |||
|
DOCOSANOL
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
PRIMARY | |||
|
211-546-6
Created by
admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
|
PRIMARY |
ACTIVE MOIETY